Blueprint Medicines (BPMC) Tops Q2 EPS by 49c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Blueprint Medicines (BPMC) PT Raised to $155 at Stifel
August 1, 2024 12:14 PM EDTStifel analyst Bradley Canino raised the price target on Blueprint Medicines (NASDAQ: BPMC) to $155.00 (from $150.00) while maintaining a Buy rating.
The analyst comments "A 13% Ayvakit beat and 11% increase to the FY24 Ayvakit guidance midpoint is fundamentally positive, but for today at least... More
